Flat-handed manual lymphatic drainage strokes over a client's abdomen at Renu in Calgary

Does chemotherapy raise lymphedema risk?

Q: My arm puffed up during docetaxel. Is that lymphedema?

Not necessarily. Docetaxel and paclitaxel are known to induce fluid retention, and in a Japanese study of 180 women with arm swelling after taxanes, 64 turned out to have fluid retention only on lymphography rather than lymphedema. Swelling in both arms, or that settles after the cycle, points toward the drug; one-sided swelling on the surgery side that persists needs measuring.

Q: Does chemotherapy before surgery raise the risk more than after?

The cohort data point that way. The NCI cites a 37.8% lymphedema incidence at a median of three years after neoadjuvant chemotherapy followed by axillary dissection, and a separate study found neoadjuvant chemotherapy independently associated with risk at an odds ratio of 2.10. Both cohorts also had dissection and radiation, so the chemotherapy effect sits on top of surgery, not instead of it.

Q: Should I stop measuring my arm while I am on chemotherapy?

No. The NLN asks for screening from a preoperative baseline onward, with high-risk people measured as often as every three months in the first two years, and lymphedema in the neoadjuvant cohort was still accumulating at three years. Chemotherapy is part of that window, not a pause in it.

Q: Is there a link between chemotherapy neuropathy and lymphedema?

One study found one. Among women with arm swelling after taxanes, peripheral neuropathy was present in 60.3% of those with confirmed lymphedema against 40.6% of those with fluid retention only. The authors suggested neuropathy may contribute to lymphedema, but it is a single study and the mechanism is not settled.

Pre-surgery chemotherapy is a risk factor in several cohorts and taxanes cause fluid retention, but a matched study of 1,494 women found no taxane effect.

By The Renu lymphatic and massage team · 7 min read

Chemotherapy is a possible contributor rather than a proven cause of lymphedema. Neoadjuvant chemotherapy appears as a risk factor in several cohorts, with an odds ratio of 2.10 in one and a 37.8% incidence after neoadjuvant chemotherapy plus axillary dissection in another, and taxanes can cause temporary fluid retention that is easy to mistake for lymphedema. But a propensity-matched analysis of 1,494 women found taxane-based adjuvant chemotherapy was not an independent risk factor (odds ratio 0.959), and the National Lymphedema Network lists taxanes among postulated, not established, risk factors. The risk rises when taxanes are followed by supraclavicular radiation, and measurement should not pause during chemotherapy.

If your arm or hand went puffy somewhere around the third cycle of docetaxel or paclitaxel, you are asking the right question, and the answer has two halves: what the drugs do to fluid in the short term, and what the cohorts say about lymphedema in the long term.

What the position statements say

The NLN’s 2026 risk-reduction statement names the strongest risk factor for breast cancer-related lymphedema as axillary lymph node dissection, with regional nodal irradiation, elevated body mass index, low-volume swelling and Black race or Hispanic ethnicity as other established factors. Taxane-based chemotherapy and targeted therapies appear in a separate sentence, as “other postulated risk factors”, alongside anatomic predisposition and cording. Its 2025 diagnosis statement sorts the evidence the same way, listing taxane-based chemotherapy among “less clear factors” with axillary web syndrome and genetic predisposition.

That placement is the fairest one-line answer: chemotherapy is suspected, not established, and the surgery and radiation that usually accompany it carry most of the weight.

Chemotherapy before surgery

The clearest signal is for neoadjuvant chemotherapy, given before the operation. The NCI’s PDQ summary cites two cohorts. In the prospective ACOSOG-Z1071 study of neoadjuvant chemotherapy followed by axillary lymph node dissection, the incidence of lymphedema after a median follow-up of three years was 37.8% (95% CI 33.1% to 43.2%), and the duration of neoadjuvant chemotherapy was among the factors associated with lymphedema symptoms (hazard ratio 1.48), with increasing body mass index and the number of nodes removed and involved. In a separate two-year prospective study of 304 women who had axillary dissection and radiation therapy, receipt of neoadjuvant chemotherapy was independently associated with increased risk (odds ratio 2.10, 95% CI 1.16 to 3.95, P = .01), alongside Black race, Hispanic ethnicity, older age and longer follow-up.

Read the setting carefully. Every woman in both cohorts had an axillary dissection, and the second cohort also had radiation. Neoadjuvant chemotherapy is a marker of more extensive disease and more extensive local treatment, and the studies cannot fully separate the drug from the company it keeps. What they do show is that a woman who had chemotherapy first, then a dissection, sits in a high-risk group and should be screened like one. Why that screening needs a starting point is on baseline arm measurements before breast cancer surgery.

Taxanes: fluid retention is not the same as lymphedema

Docetaxel and paclitaxel have been used in taxane-based chemotherapy for breast cancer and are known to induce fluid retention; that is the opening premise of Tokumoto’s 2022 study, which is the most useful paper for anyone whose arm swelled mid-chemotherapy. The authors enrolled 180 women who had completed full-dose taxane chemotherapy and complained of upper-extremity swelling, and used indocyanine green lymphography, which images the lymphatic vessels themselves, to decide who actually had lymphedema. The answer was 116 with lymphedema and 64 with fluid retention only.

The two groups differed in the ways you would expect if surgery and radiation, not the drug, were doing the damage. The lymphedema group had far higher rates of axillary dissection (98.3% against 56.3%), lymph node irradiation (68.1% against 20.3%) and neoadjuvant chemotherapy (14.7% against 3.1%). Docetaxel was more common in the lymphedema group too (62.9% against 34.4%), so the drug is not off the hook, but a third of the women who thought they had lymphedema had taxane fluid retention instead.

Two further studies bracket the question:

Study	Design	What it found about taxanes
Kang 2026, 1,494 patients	Retrospective, lymphedema by limb circumference, propensity score matching	Taxane-based adjuvant chemotherapy not associated with lymphedema before matching (OR 0.979) or after (OR 0.959, 95% CI 0.540 to 1.672, P = .885); not an independent risk factor
Horisawa 2024, 214 patients after axillary dissection	Cross-sectional at one year or more, 2 cm circumference difference	24% had objective lymphedema; supraclavicular irradiation was the only significant factor; taxanes followed by supraclavicular radiation more likely a risk than dissection alone; docetaxel and paclitaxel did not differ
PSEI trial secondary analysis, 918 women (cited by the NCI)	Prospective surveillance trial	Taxane-based chemotherapy listed among factors associated with risk (P < .001), with dissection, regional radiation, BMI over 30 and rurality

The honest reading is that taxanes on their own have not been shown to cause lymphedema once surgery and radiation are accounted for, that they can produce swelling that looks like it, and that the combination of a taxane regimen followed by radiation to the supraclavicular field is where the cohort data turn worrying. If that combination is on your plan, lymphedema risk after regional node radiation explains the radiation half.

Neuropathy and swelling travel together

Tokumoto’s study also compared eight taxane side effects between the two groups and found one difference: peripheral neuropathy was present in 60.3% of the women with lymphedema and 40.6% of those with fluid retention only (P = .01). The authors’ interpretation was that neuropathy induced by taxanes may itself contribute to lymphedema. That is one study and one proposed mechanism, so treat it as a reason to mention tingling and numbness at your lymphedema assessment rather than as a settled fact. What massage can and cannot do for the neuropathy itself is on massage for chemotherapy-induced neuropathy.

Telling transient swelling from lymphedema

Nobody should decide this at home, but the questions a Certified Lymphedema Therapist asks, drawn from the NLN’s diagnosis statement, show which way the evidence leans:

One side or both? Taxane fluid retention tends to be general; lymphedema from node treatment is on the treated side.
Does it settle overnight or with elevation? Stage 1 lymphedema is reversible swelling that subsides with elevation; later stages do not, and drug-related fluid often follows the cycle.
What does it feel like? Heaviness, tightness, a sense of swelling or tingling are the symptoms the NLN wants reported.
What does the tape say? Girth measurements converted to volume and compared with a preoperative baseline, with a relative volume change rather than a fixed cut-off, separate a real asymmetry from a general puffiness. The NLN is explicit that measurements sit beside symptoms and examination, never alone.

How lymphedema is diagnosed and staged is explained in the Learning Centre’s lymphedema and lipedema page.

Why measuring should not pause during chemotherapy

The NLN asks that people at risk be screened longitudinally from a preoperative baseline, with high-risk individuals measured as often as every three months for the first two years and less often in years three to five, and its diagnosis statement says screening should continue for at least five years. Chemotherapy falls squarely inside that window. In the neoadjuvant cohort cited by the NCI, lymphedema was still accumulating at a median of three years. Pausing measurements because “the swelling is probably the drugs” is how a subclinical change becomes an established one; measuring through chemotherapy is how taxane fluid retention gets recognized for what it is, and real lymphedema gets caught at the stage where a short course of compression still works.

When to call your oncology team

Swelling in both arms, the face or the legs, or sudden weight gain, during a taxane cycle: this is a drug effect your oncologist manages and may want to know about before the next infusion.
Swelling on the treated side only, or swelling that has not settled after the cycle, so the arm can be measured.
Redness, warmth, pain, fever or chills in the arm, the same day; the NLN treats a suspected infection in an at-risk limb as an urgent medical event, and chemotherapy lowers your defences.
New numbness, tingling or weakness in the hands or feet, which your oncologist needs to grade before the next dose.

Where Renu fits in

We cannot tell you whether your regimen will cause lymphedema, and we would be wary of anyone who claims to. We can measure both arms against a baseline, examine the tissue, and say whether what you are feeling looks like general fluid retention or a one-sided lymphatic change, then repeat the measurement after the cycle. Meeghan Mackenzie, our Certified Lymphedema Therapist, treats confirmed lymphedema with complete decongestive therapy. If you also want a massage during treatment for comfort, the adjustments for infusion days, ports and blood counts are on massage during chemotherapy.

Questions people ask

My arm puffed up during docetaxel. Is that lymphedema?

Not necessarily. Docetaxel and paclitaxel are known to induce fluid retention, and in a Japanese study of 180 women with arm swelling after taxanes, 64 turned out to have fluid retention only on lymphography rather than lymphedema. Swelling in both arms, or that settles after the cycle, points toward the drug; one-sided swelling on the surgery side that persists needs measuring.

Does chemotherapy before surgery raise the risk more than after?

The cohort data point that way. The NCI cites a 37.8% lymphedema incidence at a median of three years after neoadjuvant chemotherapy followed by axillary dissection, and a separate study found neoadjuvant chemotherapy independently associated with risk at an odds ratio of 2.10. Both cohorts also had dissection and radiation, so the chemotherapy effect sits on top of surgery, not instead of it.

Should I stop measuring my arm while I am on chemotherapy?

No. The NLN asks for screening from a preoperative baseline onward, with high-risk people measured as often as every three months in the first two years, and lymphedema in the neoadjuvant cohort was still accumulating at three years. Chemotherapy is part of that window, not a pause in it.

Is there a link between chemotherapy neuropathy and lymphedema?

One study found one. Among women with arm swelling after taxanes, peripheral neuropathy was present in 60.3% of those with confirmed lymphedema against 40.6% of those with fluid retention only. The authors suggested neuropathy may contribute to lymphedema, but it is a single study and the mechanism is not settled.